This section contains enrollment data related to BSAS licensed and/or funded treatment services, including associated geographic, service type, and socio-demographic information.
Guide PHIT Data: BSAS Substance Addiction Treatment Data
Table of Contents
What you need to know about these data
BSAS collects data only from licensed and/or funded providers across the state covering a spectrum of substance addiction treatment services, which represents a portion of all substance addiction treatment rendered in the Commonwealth. The data displayed here represent enrollments during calendar years 2014 and 2015 to BSAS licensed and/or funded treatment services stratified by geography, service types, and socio-demographic characteristics. In this dataset, unique individuals may represent many enrollments as they access different types of treatment services across the spectrum. These data do not represent the full prevalence of addiction in Massachusetts.
Explore these data
People interested in this data can stratify by geography, service types, and socio-demographic characteristics to display rates of enrollments to BSAS licensed and/or funded treatment services in Massachusetts during calendar years 2014 and 2015.
Please review the caveats in "Information about these data", below, before interpreting these data.
Information about these data
The BSAS data set includes several limitations. BSAS data does not represent all substance addiction treatment provided in the Commonwealth. BSAS only collects data from its licensed and/or funded providers. Of the data that is submitted to BSAS, outpatient treatment data is incomplete and does not include all non-BSAS paid services. BSAS does not collect data from providers that prescribe Naltrexone or from non-contracted Buprenorphine providers. Due to changes to the data collection systems, Methadone data was incomplete at the time of this report. Data collected in regards to Section 35 commitments are incomplete in the BSAS data set. A significant portion of men committed are sent to the Massachusetts Alcohol and Substance Abuse Center (MASAC) in Bridgewater (until April 2017), Plymouth and Hampden (May 2017 and onwards). Also, a significant portion of women committed were sent to the Massachusetts Committing Institution (MCI) in Framingham until July 2016. Finally, BSAS does not receive data for other FDA approved medications used to treat alcohol use disorders (i.e. Acamprosate and Disulfiram).
Socio-demographic characteristics are reliant upon self-report at the time of enrollment. Certain characteristics, such as pregnant/postpartum status, may be underreported and result in an underestimation of the true rates.
Due to continuous data updates, readers are advised not to compare the information generated using this application to statistics obtained from other reports.